Agile Therapeutics, Inc., a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced that the US Patent and Trademark Office issued US patent 9,364,487. The newly-issued patent includes claims covering the formulation of a progestin-only transdermal patch containing levonorgestrel and is expected to expire in 2032.

The company continues to explore innovative methods of delivering hormonal contraceptives through its Skinfusion transdermal delivery system. While the Company does not expect to list the newly issued patent in the FDA’s Orange Book in connection with its lead product candidate, Twirla, (ethinyl estradiol and levonorgestrel transdermal system), the patent is relevant to the company’s progestin-only patch R&D program.

The company has eight issued US patents that cover Twirla and that the company expects will be listed in the Orange Book: US 7,045,145, US 7,384,650, US 8,221,784, US 8,221,785, US 8,246978, US 8,747,888, US 8883196, and US 9050348, the latest of which extend into 2028.